Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia.
10.3760/cma.j.issn.0253-2727.2023.08.006
- Author:
Jin Yu KONG
1
;
Li Hong ZONG
1
;
Yan PU
1
;
Yin LIU
1
;
Xin KONG
1
;
Meng Yun LI
1
;
Jian ZHANG
1
;
Bao Quan SONG
1
;
Sheng Li XUE
1
;
Xiao Wen TANG
1
;
Hui Ying QIU
1
;
De Pei WU
1
Author Information
1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
- Publication Type:Journal Article
- Keywords:
Combined chemotherapy;
Leukemia, early T-cell precursor, acute;
Refractory;
Relapsed;
Venetoclax
- MeSH:
Male;
Female;
Humans;
Adult;
Retrospective Studies;
Treatment Outcome;
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*;
Precursor Cells, T-Lymphoid;
Leukemia, Myeloid, Acute/drug therapy*
- From:
Chinese Journal of Hematology
2023;44(8):649-653
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the efficacy and safety of Venetoclax combined with multidrug chemotherapy in patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia (R/R ETP-ALL) . Methods: This study retrospectively analyzed 15 patients with R/R ETP-ALL who received Venetoclax combined with multidrug chemotherapy from December 2018 to February 2022. Among them, eight cases were combined with demethylated drugs, four cases were combined with demethylated drugs and HAAG chemotherapy regimen, two cases were combined with demethylated drugs and CAG regimen, and one case was combined with Cladribine. Specific usage and dosage of Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3-28, orally; when combined with azole antifungal drugs, dosage was reduced to 100 mg/d. Results: Fifteen patients (10 males and 5 females) with R/R ETP-ALL were treated with Venetoclax and multidrug chemotherapy with a median age of 35 (12-42) years old. Of 4 refractory and 11 relapsed patients, the efficacy was evaluated on the 21th day following combined chemotherapy: the overall response rate, the complete response (CR) rate, and the CR with incomplete hematological recovery (CRi) rate were 67.7% (10/15), 60.0% (9/15), and 6.7% (1/15), respectively. For the overall study population, the 12-month overall survival (OS) rate was 60.0%, and the median OS was 17.7 months. The disease-free survival (DFS) rate of all CR patients at 12 months was 60.0%, and the median DFS did not reach. About 14 patients had Ⅲ-Ⅳ hematological toxicity, but these adverse reactions were all controllable. No adverse reaction in the nervous system and tumor lysis syndrome occurred in this study, and no adverse reaction of organs above grade Ⅲ occurred. Conclusion: Venetoclax combined with multidrug chemotherapy may be a safe and promising treatment option for patients with R/R ETP-ALL.
